

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

NCI-H716

RRID:CVCL_1581

Type: Cell Line

Proper Citation

RRID:CVCL_1581

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1581

Proper Citation: RRID:CVCL_1581

Description: Cell line NCI-H716 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cecum adenocarcinoma

Defining Citation: [PMID:1359704](#), [PMID:3479249](#), [PMID:8806089](#), [PMID:8806092](#), [PMID:8806095](#), [PMID:16418264](#), [PMID:18258742](#), [PMID:19927377](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:23272949](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29444439](#), [PMID:29787053](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Secretes high level of glucagon-like peptide 1 (GLP-1) (PubMed=29787053)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H716

Synonyms: NCI H716, H716, H-716, NCIH716

Cross References: BTO:BTO_0004747, CLO:CLO_0008108, EFO:EFO_0002301, CLDB:cl3658, AddexBio:C0009022/5006, ArrayExpress:E-MTAB-38, ArrayExpress:E-

MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-251, BCRC:60517, BioGRID_ORCS_Cell_line:520, BioSample:SAMN03473254, BioSample:SAMN10987641, cancercellines:CVCL_1581, CCRID:1101HUM-PUMC000359, CCRID:3101HUMTCHu210, CCTCC:GDC0163, Cell_Model_Passport:SIDM00779, ChEMBL-Cells:ChEMBL3308297, ChEMBL-Targets:ChEMBL2366106, CLS:305079, ColonAtlas:NCIH716, Cosmic:687536, Cosmic:908458, Cosmic:1995589, Cosmic:2302001, Cosmic-CLP:908458, DepMap:ACH-000491, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908458, GEO:GSM513917, GEO:GSM514304, GEO:GSM887443, GEO:GSM888523, GEO:GSM1346850, GEO:GSM1374759, GEO:GSM1448144, GEO:GSM1670259, IARC_TP53:21579, IARC_TP53:21743, IGRhCellID:NCIH716, KCLB:10251, LiGeA:CCLE_373, LINCS_LDP:LCL-1339, PharmacDB:NCIH716_1130_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1581, PubChem_Cell_line:CVCL_1581, SKY/M-FISH/CGH:5013, Ubigen:YC-C112, Wikidata:Q54908110

ID: CVCL_1581

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234743+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H716.

No alerts have been found for NCI-H716.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 109 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Passeri D, et al. (2026) Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. *ChemMedChem*, 21(2), e202500960.

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. *Cell reports. Medicine*, 6(7), 102213.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. *eLife*, 13.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Hosseini A, et al. (2024) Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer. *Cell reports*, 43(2), 113684.

Lee SP, et al. (2023) Thymoquinone activates imidazoline receptor to enhance glucagon-like peptide-1 secretion in diabetic rats. *Archives of medical science : AMS*, 19(1), 209.

Shon WJ, et al. (2023) Gut taste receptor type 1 member 3 is an intrinsic regulator of Western diet-induced intestinal inflammation. *BMC medicine*, 21(1), 165.

Lee SH, et al. (2023) Isosinensetin Stimulates Glucagon-like Peptide-1 Secretion via Activation of hTAS2R50 and the G α -Mediated Signaling Pathway. *International journal of molecular sciences*, 24(4).

Chapelet G, et al. (2023) Tau expression and phosphorylation in enteroendocrine cells. *Frontiers in neuroscience*, 17, 1166848.

Larraufie P, et al. (2023) Regulation of enteroendocrine cell respiration by the microbial metabolite hydrogen sulfide. *Frontiers in endocrinology*, 14, 1123364.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Zhong J, et al. (2022) Rational design of a sensitivity-enhanced tracer for discovering efficient APC-Asef inhibitors. *Nature communications*, 13(1), 4961.

Yan Y, et al. (2022) Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism. *Nature communications*, 13(1), 6408.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(23), 5190.

Sachdev P, et al. (2022) Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE). *Cancers*, 14(18).

Guo Y, et al. (2022) Circ_RNF13 Regulates the Stemness and Chemosensitivity of Colorectal Cancer by Transcriptional Regulation of DDX27 Mediated by TRIM24 Stabilization. *Cancers*, 14(24).

Lenos KJ, et al. (2022) Molecular characterization of colorectal cancer related peritoneal metastatic disease. *Nature communications*, 13(1), 4443.

Zingg D, et al. (2022) Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. *Nature*, 608(7923), 609.

Shigemori K, et al. (2022) Peripheral A β acts as a negative modulator of insulin secretion. *Proceedings of the National Academy of Sciences of the United States of America*,

119(12), e2117723119.

Jiang Y, et al. (2022) ^{18}F -FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis. *Theranostics*, 12(14), 6395.